The first non-hormonal, local period pain solution without systemic side-effects .

A female-led team dedicated to bringing our vision to life

We exist to bridge the gap in healthcare. Menstrual health needs attention and radical transformation. An effective, long-term pain management solution with minimal side effects is long overdue for menstruating people.

We are a German-based medtech company focused on developing innovative health solutions in areas of unmet medical need to serve the underserved. Our mission is simple: to improve quality of life and empower menstruating people to finally say, “no more pain, period”.

Solving an invisible problem

Menstrual pain or dysmenorrhea is a monthly recurring condition affecting more than 80% of menstruating people of reproductive age. Studies indicate 20-30% of menstruating women and girls experience pain so severely they are forced to skip school, work, sport and social activities.

Despite high prevalence, treatment options remain limited. Patients are either offered hormone-based treatments or advised to take pain medication in high dosages. Both treatment approaches are associated with severe systemic side-effects and that’s just not good enough.

  • In the United States, it has been estimated that 10-30% of all working or studying women with dysmenorrhea lose 1-2 working days per month. This health burden is sobering. At the “healthiest years of women's lives”, they suffer from a chronic pain syndrome for which no cure currently exists. 

    This amounts to an annual loss of about 600 million working hours leading to a monetary loss of roughly 2 billion USD per year. As inadequate treatment of menstrual pain may lead to chronic pain, improving care for affected women should be a major public health priority.

Introducing melioOne, the first intrauterine device (IUD) loaded with pain medication instead of hormonal contraceptives

Hormone free, localized pain management that targets the problem at its source.

Our solution is centered around an innovative polymer-based technology that enables slow and localized release directly at the site of origin. The mechanism releases sustained low dosage of pain medication to prevent and manage chronic inflammation. The dosage amount released in 12 months is equivalent to one Ibuprofen 400 pill and prevents side effects often associated with oral high drug dosage consumption. By targeting inflammation, melioOne offers a unique treatment option for individuals with dysmenorrhea and adenomyosis.